Sugi Predict

Sugi Predict / Compounds / SCHEMBL412800

SCHEMBL412800

SCHEMBL412800

O=C1O[C@@H](CO)CN1c1ccc(Br)c(F)c1

nearest known ligand 0.65

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CALML3 P27482 7/20 0.65
▸ MAOA P21397 6/20 0.57
▸ MAOB P27338 6/20 0.57
▸ CYP2C19 P33261 2/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP3A4 P08684 2/20 0.49
▸ LMNA P02545 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ SDHA P31040 1/20 0.47
▸ CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL441045 1.00 CALML3 (0.65) CALML3MAOAMAOBCYP2C19CYP2C9
SCHEMBL29406421 1.00 CALML3 (0.65) CALML3MAOAMAOBCYP2C19CYP2C9
SCHEMBL30768255 1.00 CALML3 (0.65) CALML3MAOAMAOBCYP2C19CYP2C9
SCHEMBL29021122 1.00 CALML3 (0.65) CALML3MAOAMAOBCYP2C19CYP2C9
SCHEMBL30468631 1.00 CALML3 (0.65) CALML3MAOAMAOBCYP2C19CYP2C9
SCHEMBL6052710 0.89 CALML3 (0.54) CALML3MAOAMAOBCYP2C19CYP3A4
SCHEMBL2107338 0.87 F10 (0.52) CALML3MAOAMAOBLMNAPTGS1
SCHEMBL17443340 0.87 CALML3 (0.50) CALML3MAOAMAOBLMNAPTGS1
SCHEMBL17443338 0.87 CALML3 (0.50) CALML3MAOAMAOBLMNAPTGS1
SCHEMBL16686245 0.87 CALML3 (0.50) CALML3MAOAMAOBLMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315898-B Preparation method of tedizolid phosphate and intermediate thereof, and injection 山西振东泰盛制药有限公司 2024-01-12 — — CN claimed
CN-114933596-B Preparation method of tedizolid 河北广祥制药有限公司 2023-09-05 — — CN claimed
CN-116297921-A Isomer detection method of tedizolid phosphate intermediate 成都美域高制药有限公司 2023-06-23 — — CN claimed
CN-115385959-A High-purity tedizolid phosphate and preparation method thereof 浙江尖峰药业有限公司 2022-11-25 — — CN claimed
CN-114933596-A Preparation method of tedizolid 河北广祥制药有限公司 2022-08-23 — — CN claimed
CN-111518135-B Preparation method of high-purity tedizolid phosphate 山东中医药大学 2022-05-06 — — CN claimed
CN-114315898-A Preparation method of tedizolid phosphate and intermediate thereof and injection 山西振东泰盛制药有限公司 2022-04-12 — — CN claimed
CN-111518135-A Preparation method of high-purity tedizolid phosphate 山东中医药大学 2020-08-11 — — CN claimed
CN-111116652-A Preparation method of high-purity tedizolid phosphate 山东中医药大学 2020-05-08 — — CN claimed
CN-110934880-A Compositions containing mixtures of phenyl oxazolidinone derivatives and uses thereof 黄泳华 2020-03-31 — — CN claimed
US-6869965-B2 Such as 2-methylpropyl-(4-bromo-3-fluorophenyl)carbamate PHARMACIA & UPJOHN COMPANY (US) 2005-03-22 — — US claimed
US-20040215017-A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections PHARMACIA & UPJOHN COMPANY 2004-10-28 — — US claimed
US-20030013737-A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections PHARMACIA & UPJOHN COMPANY 2003-01-16 — — US claimed
US-20260083674-A1 OXAZOLIDINONE LIPOSOME COMPOSITIONS AKAGERA MEDICINES, INC. (US) 2026-03-26 — — US disclosed
US-12365656-B2 Oxazolidinone compounds and methods of use thereof as antibacterial agents MERCK SHARP & DOHME LLC (US) 2025-07-22 — — US disclosed
US-20250064739-A1 OXAZOLIDINONE LIPOSOME COMPOSITIONS AKAGERA MEDICINES, INC. (US) 2025-02-27 — — US disclosed
US-6689769-B2 BACTERICIDES PHARMACIA & UPJOHN COMPANY 2004-02-10 — — US disclosed
EP-1349853-A2 ANTIMICROBIAL QUINOLONE DERIVATIVES AND USE OF THE SAME TO TREAT BACTERIAL INFECTIONS Pharmacia & Upjohn Company (US) 2003-10-08 — — EP disclosed
US-20030013737-A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections PHARMACIA & UPJOHN COMPANY 2003-01-16 — — US disclosed
WO-2002059116-A2 ANTIMICROBIAL QUINOLONE DERIVATIVES AND USE OF THE SAME TO TREAT BACTERIAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365656-B2 Oxazolidinone compounds and methods of use thereof as antibacterial agents OXA1L, TBCD, IL17A CALML3 3683/4885MAOA 1190/4885MAOB 689/4885
US-20030013737-A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections BRD7, BRD1, NQO2 CALML3 2894/4885MAOA 2041/4885MAOB 1965/4885
US-20250064739-A1 OXAZOLIDINONE LIPOSOME COMPOSITIONS OXA1L, CLPTM1L, AGK CALML3 2117/4885MAOA 2970/4885MAOB 2415/4885
US-20260083674-A1 OXAZOLIDINONE LIPOSOME COMPOSITIONS TBCD, SLK, PLA2G2C CALML3 2883/4885MAOA 3350/4885MAOB 3246/4885
US-20040215017-A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections BRD7, BRD1, NQO2 CALML3 2894/4885MAOA 2041/4885MAOB 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.